<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:09 -0700</creation_date>
  <update_date>2013-05-27 10:59:27 -0600</update_date>
  <accession>HMDBP00664</accession>
  <secondary_accessions>
    <accession>5937</accession>
    <accession>HMDBP03749</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Adenosine aminohydrolase</synonym>
  </synonyms>
  <gene_name>ADA</gene_name>
  <general_function>Involved in deaminase activity</general_function>
  <specific_function>Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
</specific_function>
  <pathways>
    <pathway>
      <name>Purine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00230</kegg_map_id>
    </pathway>
    <pathway>
      <name>Primary immunodeficiency</name>
      <smpdb_id/>
      <kegg_map_id>map05340</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00050</accession>
      <name>Adenosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00195</accession>
      <name>Inosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00101</accession>
      <name>Deoxyadenosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00071</accession>
      <name>Deoxyinosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01889</accession>
      <name>Theophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00051</accession>
      <name>Ammonia</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14340</accession>
      <name>Vidarabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14692</accession>
      <name>Pentostatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15109</accession>
      <name>Edetic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15110</accession>
      <name>Dipyridamole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15401</accession>
      <name>Nelarabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29956</accession>
      <name>Nebularine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenosine deaminase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>deaminase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside, nucleotide and nucleic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside and nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleoside phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>purine nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>purine nucleotide biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>purine nucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>purine ribonucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cell junction</description>
      <go_id>GO:0030054</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytoplasmic membrane-bounded vesicle lumen</description>
      <go_id>GO:0060205</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>dendrite cytoplasm</description>
      <go_id>GO:0032839</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>external side of plasma membrane</description>
      <go_id>GO:0009897</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>extracellular space</description>
      <go_id>GO:0005615</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>lysosome</description>
      <go_id>GO:0005764</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuronal cell body</description>
      <go_id>GO:0043025</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>adenosine deaminase activity</description>
      <go_id>GO:0004000</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>purine nucleoside binding</description>
      <go_id>GO:0001883</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>zinc ion binding</description>
      <go_id>GO:0008270</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>adenosine catabolic process</description>
      <go_id>GO:0006154</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>aging</description>
      <go_id>GO:0007568</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell adhesion</description>
      <go_id>GO:0007155</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dATP catabolic process</description>
      <go_id>GO:0046061</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>deoxyadenosine catabolic process</description>
      <go_id>GO:0006157</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>embryonic digestive tract development</description>
      <go_id>GO:0048566</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>germinal center B cell differentiation</description>
      <go_id>GO:0002314</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>histamine secretion</description>
      <go_id>GO:0001821</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hypoxanthine salvage</description>
      <go_id>GO:0043103</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>inosine biosynthetic process</description>
      <go_id>GO:0046103</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>liver development</description>
      <go_id>GO:0001889</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>lung alveolus development</description>
      <go_id>GO:0048286</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of adenosine receptor signaling pathway</description>
      <go_id>GO:0060169</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of circadian sleep/wake cycle, non-REM sleep</description>
      <go_id>GO:0042323</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of inflammatory response</description>
      <go_id>GO:0050728</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of leukocyte migration</description>
      <go_id>GO:0002686</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of mature B cell apoptotic process</description>
      <go_id>GO:0002906</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of mucus secretion</description>
      <go_id>GO:0070256</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of penile erection</description>
      <go_id>GO:0060407</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of thymocyte apoptotic process</description>
      <go_id>GO:0070244</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>Peyer's patch development</description>
      <go_id>GO:0048541</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>placenta development</description>
      <go_id>GO:0001890</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of alpha-beta T cell differentiation</description>
      <go_id>GO:0046638</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of B cell proliferation</description>
      <go_id>GO:0030890</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of calcium-mediated signaling</description>
      <go_id>GO:0050850</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of germinal center formation</description>
      <go_id>GO:0002636</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of heart rate</description>
      <go_id>GO:0010460</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of smooth muscle contraction</description>
      <go_id>GO:0045987</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of T cell differentiation in thymus</description>
      <go_id>GO:0033089</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of T cell receptor signaling pathway</description>
      <go_id>GO:0050862</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>purine nucleotide salvage</description>
      <go_id>GO:0032261</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>purine ribonucleoside monophosphate biosynthetic process</description>
      <go_id>GO:0009168</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of cell-cell adhesion mediated by integrin</description>
      <go_id>GO:0033632</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hydrogen peroxide</description>
      <go_id>GO:0042542</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hypoxia</description>
      <go_id>GO:0001666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to morphine</description>
      <go_id>GO:0043278</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>T cell activation</description>
      <go_id>GO:0042110</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>trophectodermal cell differentiation</description>
      <go_id>GO:0001829</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xanthine biosynthetic process</description>
      <go_id>GO:0046111</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
    <subcellular_location>Extracellular side</subcellular_location>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>Cytoplasmic vesicle lumen</subcellular_location>
    <subcellular_location>Cytoplasm</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>20</chromosome_location>
    <locus>20q13.12</locus>
    <gene_sequence>&gt;1092 bp
ATGGCCCAGACGCCCGCCTTCGACAAGCCCAAAGTAGAACTGCATGTCCACCTAGACGGA
TCCATCAAGCCTGAAACCATCTTATACTATGGCAGGAGGAGAGGGATCGCCCTCCCAGCT
AACACAGCAGAGGGGCTGCTGAACGTCATTGGCATGGACAAGCCGCTCACCCTTCCAGAC
TTCCTGGCCAAGTTTGACTACTACATGCCTGCTATCGCGGGCTGCCGGGAGGCTATCAAA
AGGATCGCCTATGAGTTTGTAGAGATGAAGGCCAAAGAGGGCGTGGTGTATGTGGAGGTG
CGGTACAGTCCGCACCTGCTGGCCAACTCCAAAGTGGAGCCAATCCCCTGGAACCAGGCT
GAAGGGGACCTCACCCCAGACGAGGTGGTGGCCCTAGTGGGCCAGGGCCTGCAGGAGGGG
GAGCGAGACTTCGGGGTCAAGGCCCGGTCCATCCTGTGCTGCATGCGCCACCAGCCCAAC
TGGTCCCCCAAGGTGGTGGAGCTGTGTAAGAAGTACCAGCAGCAGACCGTGGTGGCCATT
GACCTGGCTGGAGATGAGACCATCCCAGGAAGCAGCCTCTTGCCTGGACATGTCCAGGCC
TACCAGGAGGCTGTGAAGAGCGGCATTCACCGTACTGTCCACGCCGGGGAGGTGGGCTCG
GCCGAAGTAGTAAAAGAGGCTGTGGACATACTCAAGACAGAGCGGCTGGGACACGGCTAC
CACACCCTGGAAGACCAGGCCCTTTATAACAGGCTGCGGCAGGAAAACATGCACTTCGAG
ATCTGCCCCTGGTCCAGCTACCTCACTGGTGCCTGGAAGCCGGACACGGAGCATGCAGTC
ATTCGGCTCAAAAATGACCAGGCTAACTACTCGCTCAACACAGATGACCCGCTCATCTTC
AAGTCCACCCTGGACACTGATTACCAGATGACCAAACGGGACATGGGCTTTACTGAAGAG
GAGTTTAAAAGGCTGAACATCAATGCGGCCAAATCTAGTTTCCTCCCAGAAGATGAAAAG
AGGGAGCTTCTCGACCTGCTCTATAAAGCCTATGGGATGCCACCTTCAGCCTCTGCAGGG
CAGAACCTCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>363</residue_number>
    <molecular_weight>40764.13</molecular_weight>
    <theoretical_pi>5.944</theoretical_pi>
    <pfams>
      <pfam>
        <name>A_deaminase</name>
        <pfam_id>PF00962</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Adenosine deaminase
MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPD
FLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQA
EGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAI
DLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGY
HTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIF
KSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAG
QNL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>28380</genbank_protein_id>
  <uniprot_id>P00813</uniprot_id>
  <uniprot_name>ADA_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1M7M</pdb_id>
    <pdb_id>3IAR</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X02994</genbank_gene_id>
  <genecard_id>ADA</genecard_id>
  <geneatlas_id>ADA</geneatlas_id>
  <hgnc_id>HGNC:186</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH: Human adenosine deaminase. cDNA and complete primary amino acid sequence.  J Biol Chem. 1984 Oct 10;259(19):12101-6.</reference_text>
      <pubmed_id>6090454</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wiginton DA, Adrian GS, Hutton JJ: Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acids Res. 1984 Mar 12;12(5):2439-46.</reference_text>
      <pubmed_id>6546794</pubmed_id>
    </reference>
    <reference>
      <reference_text>Valerio D, Duyvesteyn MG, Dekker BM, Weeda G, Berkvens TM, van der Voorn L, van Ormondt H, van der Eb AJ: Adenosine deaminase: characterization and expression of a gene with a remarkable promoter. EMBO J. 1985 Feb;4(2):437-43.</reference_text>
      <pubmed_id>3839456</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wiginton DA, Kaplan DJ, States JC, Akeson AL, Perme CM, Bilyk IJ, Vaughn AJ, Lattier DL, Hutton JJ: Complete sequence and structure of the gene for human adenosine deaminase.  Biochemistry. 1986 Dec 16;25(25):8234-44.</reference_text>
      <pubmed_id>3028473</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20.  Nature. 2001 Dec 20-27;414(6866):865-71.</reference_text>
      <pubmed_id>11780052</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Orkin SH, Daddona PE, Shewach DS, Markham AF, Bruns GA, Goff SC, Kelley WN: Molecular cloning of human adenosine deaminase gene sequences.  J Biol Chem. 1983 Nov 10;258(21):12753-6.</reference_text>
      <pubmed_id>6688808</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C: Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993 Jul 23;261(5120):466-9.</reference_text>
      <pubmed_id>8101391</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Meester I, Vanham G, Kestens L, Vanhoof G, Bosmans E, Gigase P, Scharpe S: Binding of adenosine deaminase to the lymphocyte surface via CD26.  Eur J Immunol. 1994 Mar;24(3):566-70.</reference_text>
      <pubmed_id>7907293</pubmed_id>
    </reference>
    <reference>
      <reference_text>Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I: Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000 Sep;267(17):5608-13.</reference_text>
      <pubmed_id>10951221</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gines S, Marino M, Mallol J, Canela EI, Morimoto C, Callebaut C, Hovanessian A, Casado V, Lluis C, Franco R: Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J. 2002 Jan 15;361(Pt 2):203-9.</reference_text>
      <pubmed_id>11772392</pubmed_id>
    </reference>
    <reference>
      <reference_text>Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, Sang BC, Wijnands RA, Webb DR, Swanson RV: N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci. 2004 Jan;13(1):145-54.</reference_text>
      <pubmed_id>14691230</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. Epub 2009 Jul 16.</reference_text>
      <pubmed_id>19608861</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hirschhorn R, Yang DR, Israni A: An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover. Ann Hum Genet. 1994 Jan;58(Pt 1):1-9.</reference_text>
      <pubmed_id>8031011</pubmed_id>
    </reference>
    <reference>
      <reference_text>Adrian GS, Wiginton DA, Hutton JJ: Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines. Mol Cell Biol. 1984 Sep;4(9):1712-7.</reference_text>
      <pubmed_id>6208479</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bonthron DT, Markham AF, Ginsburg D, Orkin SH: Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency. J Clin Invest. 1985 Aug;76(2):894-7.</reference_text>
      <pubmed_id>3839802</pubmed_id>
    </reference>
    <reference>
      <reference_text>Akeson AL, Wiginton DA, Dusing MR, States JC, Hutton JJ: Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts. J Biol Chem. 1988 Nov 5;263(31):16291-6.</reference_text>
      <pubmed_id>3182793</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hirschhorn R, Tzall S, Ellenbogen A, Orkin SH: Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency. J Clin Invest. 1989 Feb;83(2):497-501.</reference_text>
      <pubmed_id>2783588</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hirschhorn R: Identification of two new missense mutations (R156C and S291L) in two ADA- SCID patients unusual for response to therapy with partial exchange transfusions. Hum Mutat. 1992;1(2):166-8.</reference_text>
      <pubmed_id>1284479</pubmed_id>
    </reference>
    <reference>
      <reference_text>Santisteban I, Arredondo-Vega FX, Kelly S, Mary A, Fischer A, Hummell DS, Lawton A, Sorensen RU, Stiehm ER, Uribe L, et al.: Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype. J Clin Invest. 1993 Nov;92(5):2291-302.</reference_text>
      <pubmed_id>8227344</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yang DR, Huie ML, Hirschhorn R: Homozygosity for a missense mutation (G20R) associated with neonatal onset adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID). Clin Immunol Immunopathol. 1994 Feb;70(2):171-5.</reference_text>
      <pubmed_id>8299233</pubmed_id>
    </reference>
    <reference>
      <reference_text>Santisteban I, Arredondo-Vega FX, Kelly S, Loubser M, Meydan N, Roifman C, Howell PL, Bowen T, Weinberg KI, Schroeder ML, et al.: Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. Hum Mol Genet. 1995 Nov;4(11):2081-7.</reference_text>
      <pubmed_id>8589684</pubmed_id>
    </reference>
    <reference>
      <reference_text>Santisteban I, Arredondo-Vega FX, Kelly S, Debre M, Fischer A, Perignon JL, Hilman B, elDahr J, Dreyfus DH, Gelfand EW, et al.: Four new adenosine deaminase mutations, altering a zinc-binding histidine, two conserved alanines, and a 5' splice site. Hum Mutat. 1995;5(3):243-50.</reference_text>
      <pubmed_id>7599635</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hirschhorn R, Borkowsky W, Jiang CK, Yang DR, Jenkins T: Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA-) individuals that result in differing biochemical and metabolic phenotypes. Hum Genet. 1997 Jul;100(1):22-9.</reference_text>
      <pubmed_id>9225964</pubmed_id>
    </reference>
    <reference>
      <reference_text>Arrendondo-Vega FX, Santisteban I, Notarangelo LD, El Dahr J, Buckley R, Roifman C, Conley ME, Hershfield MS: Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del. Mutations in brief no. 142. Online. Hum Mutat. 1998;11(6):482.</reference_text>
      <pubmed_id>10200056</pubmed_id>
    </reference>
    <reference>
      <reference_text>Retey JV, Adam M, Honegger E, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP: A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15676-81. Epub 2005 Oct 12.</reference_text>
      <pubmed_id>16221767</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-6. Epub 2008 Sep 4.</reference_text>
      <pubmed_id>18772397</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Kopff M, Kopff A, Puczkowski S: [Adenosine deaminase: isoenzymes ADA1 and ADA2].  Pol Merkur Lekarski. 1997 Dec;3(18):288-90.</reference_text>
        <pubmed_id>9523470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Saboury AA, Bagheri S, Ataie G, Amanlou M, Moosavi-Movahedi AA, Hakimelahi GH, Cristalli G, Namaki S: Binding properties of adenosine deaminase interacted with theophylline.  Chem Pharm Bull (Tokyo). 2004 Oct;52(10):1179-82.</reference_text>
        <pubmed_id>15467230</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Singh LS, Sharma R: Purification and characterization of intestinal adenosine deaminase from mice.  Mol Cell Biochem. 2000 Jan;204(1-2):127-34.</reference_text>
        <pubmed_id>10718633</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Bandyopadhyay BC, Poddar MK: Theophylline-induced changes in mammalian adenosine deaminase activity and corticosterone status: possible relation to immune response. Methods Find Exp Clin Pharmacol. 1997 Apr;19(3):181-4.</reference_text>
        <pubmed_id>9203166</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vidarabine</name>
        <accession>HMDB14340</accession>
      </metabolite>
      <reference>
        <reference_text>Agarwal RP, Blatt J, Miser J, Sallan S, Lipton JM, Reaman GH, Holcenberg J, Poplack DG: Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Cancer Res. 1982 Sep;42(9):3884-6.</reference_text>
        <pubmed_id>6980706</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vidarabine</name>
        <accession>HMDB14340</accession>
      </metabolite>
      <reference>
        <reference_text>Balzarini J, De Clercq E: The antiviral activity of 9-beta-D-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine. Biochem Biophys Res Commun. 1989 Feb 28;159(1):61-7.</reference_text>
        <pubmed_id>2538128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vidarabine</name>
        <accession>HMDB14340</accession>
      </metabolite>
      <reference>
        <reference_text>Cristalli G, Franchetti P, Grifantini M, Vittori S, Lupidi G, Riva F, Bordoni T, Geroni C, Verini MA: Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem. 1988 Feb;31(2):390-3.</reference_text>
        <pubmed_id>3339608</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentostatin</name>
        <accession>HMDB14692</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentostatin</name>
        <accession>HMDB14692</accession>
      </metabolite>
      <reference>
        <reference_text>Jackson RC, Leopold WR, Ross DA: The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase. Adv Enzyme Regul. 1986;25:125-39.</reference_text>
        <pubmed_id>2433905</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentostatin</name>
        <accession>HMDB14692</accession>
      </metabolite>
      <reference>
        <reference_text>Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years.  J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.</reference_text>
        <pubmed_id>17309302</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentostatin</name>
        <accession>HMDB14692</accession>
      </metabolite>
      <reference>
        <reference_text>Cabanillas F: Purine nucleoside analogs in indolent non-Hodgkin's lymphoma.  Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.</reference_text>
        <pubmed_id>10887639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edetic Acid</name>
        <accession>HMDB15109</accession>
      </metabolite>
      <reference>
        <reference_text>Abu-Shady MR, Elshafei AM, el-Beih FM, Mohamed LA: Properties of adenosine deaminase in extracts of Asperigillus terricola.  Acta Microbiol Pol. 1994;43(3-4):305-11.</reference_text>
        <pubmed_id>7740980</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent.  Clin Ther. 2007 Sep;29(9):1887-99.</reference_text>
        <pubmed_id>18035189</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii.</reference_text>
        <pubmed_id>19825456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28.</reference_text>
        <pubmed_id>20616909</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>Cooper TM: Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag. 2007 Dec;3(6):1135-41.</reference_text>
        <pubmed_id>18516261</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen MH, Johnson JR, Justice R, Pazdur R: FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008 Jun;13(6):709-14.</reference_text>
        <pubmed_id>18586926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelarabine</name>
        <accession>HMDB15401</accession>
      </metabolite>
      <reference>
        <reference_text>Gandhi V, Keating MJ, Bate G, Kirkpatrick P: Nelarabine.  Nat Rev Drug Discov. 2006 Jan;5(1):17-8.</reference_text>
        <pubmed_id>16485343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebularine</name>
        <accession>HMDB29956</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebularine</name>
        <accession>HMDB29956</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebularine</name>
        <accession>HMDB29956</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
